NASDAQ:ASND - Ascendis Pharma Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$67.00 +0.12 (+0.18 %)
(As of 05/22/2018 01:49 PM ET)
Previous Close$66.59
Today's Range$66.00 - $67.00
52-Week Range$21.95 - $70.50
Volume1,025 shs
Average Volume101,945 shs
Market Capitalization$2.75 billion
P/E Ratio-15.47
Dividend YieldN/A
Beta0.65

About Ascendis Pharma (NASDAQ:ASND)

Ascendis Pharma logoAscendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia. It also has strategic collaborations with Sanofi to develop TransCon Peptides for the treatment of diabetes; and Genentech and Roche to develop TransCon anti-vascular endothelial growth factor (VEGF), a compound to support injection of anti-VEGF in ophthalmology. Ascendis Pharma A/S was founded in 2006 and is headquartered in Hellerup, Denmark.

Receive ASND News and Ratings via Email

Sign-up to receive the latest news and ratings for ASND and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ASND
CUSIPN/A
Phone45-7022-2244

Debt

Debt-to-Equity RatioN/A
Current Ratio8.61
Quick Ratio8.61

Price-To-Earnings

Trailing P/E Ratio-15.47
Forward P/E Ratio-17.63
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.80 million
Price / Sales1,545.47
Cash FlowN/A
Price / CashN/A
Book Value$5.82 per share
Price / Book11.51

Profitability

EPS (Most Recent Fiscal Year)($4.33)
Net Income$-140,040,000.00
Net Margins-8,156.09%
Return on Equity-74.67%
Return on Assets-66.95%

Miscellaneous

Employees101
Outstanding Shares41,520,000

Ascendis Pharma (NASDAQ:ASND) Frequently Asked Questions

What is Ascendis Pharma's stock symbol?

Ascendis Pharma trades on the NASDAQ under the ticker symbol "ASND."

How were Ascendis Pharma's earnings last quarter?

Ascendis Pharma (NASDAQ:ASND) issued its quarterly earnings data on Wednesday, March, 28th. The biotechnology company reported ($1.08) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.92) by $0.16. The biotechnology company had revenue of $0.33 million for the quarter, compared to analyst estimates of $0.58 million. Ascendis Pharma had a negative return on equity of 74.67% and a negative net margin of 8,156.09%. View Ascendis Pharma's Earnings History.

When is Ascendis Pharma's next earnings date?

Ascendis Pharma is scheduled to release their next quarterly earnings announcement on Wednesday, May, 30th 2018. View Earnings Estimates for Ascendis Pharma.

What price target have analysts set for ASND?

7 analysts have issued 1 year price targets for Ascendis Pharma's stock. Their forecasts range from $51.00 to $78.00. On average, they anticipate Ascendis Pharma's share price to reach $67.3333 in the next twelve months. View Analyst Ratings for Ascendis Pharma.

What are Wall Street analysts saying about Ascendis Pharma stock?

Here are some recent quotes from research analysts about Ascendis Pharma stock:
  • 1. According to Zacks Investment Research, "Ascendis Pharma A/S is a biopharmaceutical company. The company's product pipeline consist of TransCon Human Growth Hormone, TransCon Treprostinil, TransCon Insulin, TransCon Peptide and TransCon Ranibizumab, which are in different clinical stage, for the treatments of hormone deficiency, endocrinology, central nervous system disorders, infectious diseases and diabetes. Its technology includes TransCon which develop prodrug therapies. Ascendis Pharma A/S is based in Denmark. " (3/1/2018)
  • 2. Wedbush analysts commented, "The Wedbush View. We see ASND as an attractive investment in the short- and longer-term with pipeline progress and competitor data release in the coming months, plus results from the pivotal heiGHt trial in late 2018. Cash runway into Q4:18. Ascendis reported revenues of €0.37MM and a (loss) of €(0.78)." (5/24/2017)

Are investors shorting Ascendis Pharma?

Ascendis Pharma saw a decrease in short interest in the month of April. As of April 13th, there was short interest totalling 226,374 shares, a decrease of 58.8% from the March 30th total of 549,544 shares. Based on an average daily trading volume, of 104,419 shares, the short-interest ratio is presently 2.2 days. Currently, 0.6% of the shares of the company are short sold.

Who are some of Ascendis Pharma's key competitors?

Who are Ascendis Pharma's key executives?

Ascendis Pharma's management team includes the folowing people:
  • Mr. Michael Wolff Jensen L.L.M., Chairman, Sr. VP, Gen. Counsel and Member of Exec. Board (Age 47)
  • Mr. Jan Møller Mikkelsen, Chief Exec. Officer, Pres, Member of Exec. Board and Exec. Director (Age 58)
  • Mr. Scott T. Smith, Sr. VP & CFO (Age 44)
  • Mrs. Lotte Sønderbjerg, Chief Admin. Officer, Sr. VP and Member of Exec. Board (Age 57)
  • Dr. Grethe Rasmussen Ph.D., Sr. VP of Product Devel. and Member of Exec. Board (Age 56)

When did Ascendis Pharma IPO?

(ASND) raised $85 million in an IPO on Wednesday, January 28th 2015. The company issued 5,000,000 shares at $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners served as the underwriters for the IPO and Wells Fargo Securities was co-manager.

Has Ascendis Pharma been receiving favorable news coverage?

News headlines about ASND stock have trended somewhat positive recently, according to Accern Sentiment. Accern scores the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Ascendis Pharma earned a media sentiment score of 0.19 on Accern's scale. They also gave news stories about the biotechnology company an impact score of 47.20 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future.

Who are Ascendis Pharma's major shareholders?

Ascendis Pharma's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Sofinnova Ventures Inc (5.97%), venBio Select Advisor LLC (4.97%), Farallon Capital Management LLC (3.10%), Millennium Management LLC (1.60%), VHCP Management II LLC (1.41%) and Acuta Capital Partners LLC (1.31%). View Institutional Ownership Trends for Ascendis Pharma.

Which institutional investors are selling Ascendis Pharma stock?

ASND stock was sold by a variety of institutional investors in the last quarter, including VHCP Management II LLC, Foresite Capital Management IV LLC, Lord Abbett & CO. LLC, DAFNA Capital Management LLC, Foresite Capital Management III LLC, Sphera Funds Management LTD., University of Notre Dame DU Lac and BlackRock Inc.. View Insider Buying and Selling for Ascendis Pharma.

Which institutional investors are buying Ascendis Pharma stock?

ASND stock was bought by a variety of institutional investors in the last quarter, including Sofinnova Ventures Inc, Farallon Capital Management LLC, Franklin Resources Inc., venBio Select Advisor LLC, Millennium Management LLC, OppenheimerFunds Inc., New York State Common Retirement Fund and Tiverton Asset Management LLC. View Insider Buying and Selling for Ascendis Pharma.

How do I buy shares of Ascendis Pharma?

Shares of ASND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ascendis Pharma's stock price today?

One share of ASND stock can currently be purchased for approximately $67.00.

How big of a company is Ascendis Pharma?

Ascendis Pharma has a market capitalization of $2.75 billion and generates $1.80 million in revenue each year. The biotechnology company earns $-140,040,000.00 in net income (profit) each year or ($4.33) on an earnings per share basis. Ascendis Pharma employs 101 workers across the globe.

How can I contact Ascendis Pharma?

Ascendis Pharma's mailing address is TUBORG BOULEVARD 5, HELLERUP G7, 2900. The biotechnology company can be reached via phone at 45-7022-2244 or via email at [email protected]


MarketBeat Community Rating for Ascendis Pharma (ASND)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  157 (Vote Outperform)
Underperform Votes:  138 (Vote Underperform)
Total Votes:  295
MarketBeat's community ratings are surveys of what our community members think about Ascendis Pharma and other stocks. Vote "Outperform" if you believe ASND will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ASND will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Ascendis Pharma (NASDAQ:ASND) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
7 Wall Street analysts have issued ratings and price targets for Ascendis Pharma in the last 12 months. Their average twelve-month price target is $67.3333, suggesting that the stock has a possible upside of 0.50%. The high price target for ASND is $78.00 and the low price target for ASND is $51.00. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.863.002.862.83
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $67.3333$67.3333$51.8333$36.4517
Price Target Upside: 0.50% upside3.21% upside6.37% upside0.81% downside

Ascendis Pharma (NASDAQ:ASND) Consensus Price Target History

Price Target History for Ascendis Pharma (NASDAQ:ASND)

Ascendis Pharma (NASDAQ:ASND) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/15/2018WedbushReiterated RatingOutperform$76.00LowView Rating Details
4/2/2018Leerink SwannReiterated RatingMkt Perform ➝ Market Perform$37.00 ➝ $64.00HighView Rating Details
3/21/2018JPMorgan ChaseBoost Price TargetOverweight$75.00HighView Rating Details
3/20/2018Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$50.00 ➝ $78.00HighView Rating Details
1/25/2018Bank of AmericaBoost Price TargetBuy ➝ Buy$45.00 ➝ $60.00HighView Rating Details
1/19/2018HC WainwrightReiterated RatingBuyMediumView Rating Details
9/22/2017Wells FargoReiterated RatingBuy$51.00HighView Rating Details
(Data available from 5/22/2016 forward)

Earnings

Ascendis Pharma (NASDAQ:ASND) Earnings History and Estimates Chart

Earnings by Quarter for Ascendis Pharma (NASDAQ:ASND)

Ascendis Pharma (NASDAQ:ASND) Earnings Estimates

2018 EPS Consensus Estimate: ($3.89)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.95)($0.95)($0.95)
Q2 20181($0.96)($0.96)($0.96)
Q3 20181($0.98)($0.98)($0.98)
Q4 20181($1.00)($1.00)($1.00)

Ascendis Pharma (NASDAQ ASND) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/30/2018($0.93)N/AView Earnings Details
3/28/2018Q4 2017($0.92)($1.08)$0.58 million$0.33 millionViewN/AView Earnings Details
11/16/2017Q3 2017($0.85)($1.22)$0.95 million$0.51 millionViewN/AView Earnings Details
8/18/20176/30/2017($0.80)($1.04)$0.78 million$0.44 millionViewN/AView Earnings Details
5/23/2017Q1($0.64)($0.83)$1.10 million$0.40 millionViewN/AView Earnings Details
3/22/2017Q4($0.61)($0.55)$1.22 million$1.13 millionViewN/AView Earnings Details
11/30/2016Q316($0.71)($0.80)$1.25 million$1.30 millionViewN/AView Earnings Details
8/31/2016Q216($0.67)($0.60)$1.11 million$1.28 millionViewListenView Earnings Details
5/19/2016Q1($0.55)($0.90)$1.39 millionViewN/AView Earnings Details
4/14/2016Q4 2015($0.46)($0.54)$2.17 millionViewN/AView Earnings Details
11/12/2015Q3 2015($0.57)($0.34)$2.25 million$2.37 millionViewN/AView Earnings Details
8/24/2015Q2($0.48)($0.70)$2.23 million$2.15 millionViewN/AView Earnings Details
5/18/2015Q115($0.39)$0.0670$2.24 million$2.38 millionViewListenView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Ascendis Pharma (NASDAQ:ASND) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Ascendis Pharma (NASDAQ ASND) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 90.53%
Insider Trading History for Ascendis Pharma (NASDAQ:ASND)
Institutional Ownership by Quarter for Ascendis Pharma (NASDAQ:ASND)

Ascendis Pharma (NASDAQ ASND) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Ascendis Pharma (NASDAQ ASND) News Headlines

Source:
DateHeadline
Ascendis Pharma (ASND) Given Consensus Rating of "Buy" by AnalystsAscendis Pharma (ASND) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - May 21 at 5:33 PM
Ascendis Pharma A/S Announces First Quarter 2018 Financial Results and Business Update Conference Call on May 30Ascendis Pharma A/S Announces First Quarter 2018 Financial Results and Business Update Conference Call on May 30
finance.yahoo.com - May 16 at 4:30 PM
Ascendis Pharma (ASND) Given Outperform Rating at WedbushAscendis Pharma (ASND) Given Outperform Rating at Wedbush
www.americanbankingnews.com - May 15 at 1:56 PM
Stock Traders Buy High Volume of Ascendis Pharma Call Options (ASND)Stock Traders Buy High Volume of Ascendis Pharma Call Options (ASND)
www.americanbankingnews.com - May 15 at 6:48 AM
Wired News - Ascendis Pharma Dosed First Subjects in First-in-Human Phase-1 Trial of TransCon CNPWired News - Ascendis Pharma Dosed First Subjects in First-in-Human Phase-1 Trial of TransCon CNP
finance.yahoo.com - May 10 at 9:41 AM
Zacks: Analysts Anticipate Ascendis Pharma (ASND) Will Announce Quarterly Sales of $300,000.00Zacks: Analysts Anticipate Ascendis Pharma (ASND) Will Announce Quarterly Sales of $300,000.00
www.americanbankingnews.com - May 9 at 2:21 AM
Ascendis Pharma A/S Announces Dosing of First Subjects in Phase 1 Trial of TransCon CNPAscendis Pharma A/S Announces Dosing of First Subjects in Phase 1 Trial of TransCon CNP
finance.yahoo.com - May 8 at 9:23 AM
Zacks: Brokerages Expect Ascendis Pharma (ASND) Will Announce Earnings of -$0.93 Per ShareZacks: Brokerages Expect Ascendis Pharma (ASND) Will Announce Earnings of -$0.93 Per Share
www.americanbankingnews.com - May 7 at 5:22 PM
Ascendis Pharma A/S Announces Poster Presentation on TransCon PTH Phase 1 Trial at the European Congress of EndocrinologyAscendis Pharma A/S Announces Poster Presentation on TransCon PTH Phase 1 Trial at the European Congress of Endocrinology
finance.yahoo.com - May 7 at 4:37 PM
ValuEngine Upgrades Ascendis Pharma (ASND) to "Strong-Buy"ValuEngine Upgrades Ascendis Pharma (ASND) to "Strong-Buy"
www.americanbankingnews.com - May 4 at 12:21 AM
Ascendis Pharma (ASND) Short Interest Down 58.8% in AprilAscendis Pharma (ASND) Short Interest Down 58.8% in April
www.americanbankingnews.com - April 28 at 1:39 AM
Ascendis Pharma (ASND) Given Consensus Recommendation of "Buy" by BrokeragesAscendis Pharma (ASND) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 26 at 5:36 PM
Ascendis Pharma A/S Announces Upcoming Investor PresentationsAscendis Pharma A/S Announces Upcoming Investor Presentations
finance.yahoo.com - April 25 at 9:34 AM
REFILE-High-profile investors bet on stocks tied to millennials -Sohn ConferenceREFILE-High-profile investors bet on stocks tied to millennials -Sohn Conference
www.reuters.com - April 24 at 9:27 AM
High-profile investors bet on stocks tied to millennials - Sohn ConferenceHigh-profile investors bet on stocks tied to millennials - Sohn Conference
finance.yahoo.com - April 23 at 4:25 PM
$300,000.00 in Sales Expected for Ascendis Pharma (ASND) This Quarter$300,000.00 in Sales Expected for Ascendis Pharma (ASND) This Quarter
www.americanbankingnews.com - April 22 at 2:36 AM
Ascendis Pharma (ASND) Expected to Announce Earnings of -$0.93 Per ShareAscendis Pharma (ASND) Expected to Announce Earnings of -$0.93 Per Share
www.americanbankingnews.com - April 20 at 3:14 PM
Ascendis Pharma (ASND) Rating Reiterated by WedbushAscendis Pharma (ASND) Rating Reiterated by Wedbush
www.americanbankingnews.com - April 20 at 11:55 AM
Ascendis Pharma (ASND) Lowered to Sell at BidaskClubAscendis Pharma (ASND) Lowered to Sell at BidaskClub
www.americanbankingnews.com - April 11 at 10:42 PM
Consolidated Research: 2018 Summary Expectations for Ternium S.A, CNB Financial, Barrick Gold, NewConsolidated Research: 2018 Summary Expectations for Ternium S.A, CNB Financial, Barrick Gold, New
www.nasdaq.com - April 11 at 10:08 AM
Q3 2018 EPS Estimates for Ascendis Pharma (ASND) Decreased by WedbushQ3 2018 EPS Estimates for Ascendis Pharma (ASND) Decreased by Wedbush
www.americanbankingnews.com - April 9 at 1:52 AM
Wired News – Synlogic Announced First Subject Dosed in Phase-1b/2a Trial of SYNB1020 for Treatment of Hyperammonemia in Patients with CirrhosisWired News – Synlogic Announced First Subject Dosed in Phase-1b/2a Trial of SYNB1020 for Treatment of Hyperammonemia in Patients with Cirrhosis
finance.yahoo.com - April 4 at 5:05 PM
Ascendis Pharmas (ASND) Outperform Rating Reiterated at WedbushAscendis Pharma's (ASND) Outperform Rating Reiterated at Wedbush
www.americanbankingnews.com - April 4 at 4:10 PM
Ascendis Pharma (ASND) Upgraded to "Buy" at ValuEngineAscendis Pharma (ASND) Upgraded to "Buy" at ValuEngine
www.americanbankingnews.com - April 3 at 7:34 PM
Ascendis Pharma (ASND) Price Target Raised to $64.00 at Leerink SwannAscendis Pharma (ASND) Price Target Raised to $64.00 at Leerink Swann
www.americanbankingnews.com - April 2 at 10:12 AM
Ascendis Pharma A/S Appoints Thomas A. Larson as Chief Commercial OfficerAscendis Pharma A/S Appoints Thomas A. Larson as Chief Commercial Officer
globenewswire.com - April 2 at 9:57 AM
Ascendis Pharma (ASND) PT Raised to $64 at Leerink PartnersAscendis Pharma (ASND) PT Raised to $64 at Leerink Partners
www.streetinsider.com - April 2 at 9:57 AM
Ascendis Pharma A/S (ASND) Given Consensus Recommendation of "Buy" by BrokeragesAscendis Pharma A/S (ASND) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 1 at 5:28 PM
JPMorgan Chase & Co. Analysts Give Ascendis Pharma A/S (ASND) a $50.00 Price TargetJPMorgan Chase & Co. Analysts Give Ascendis Pharma A/S (ASND) a $50.00 Price Target
www.americanbankingnews.com - March 30 at 11:40 PM
Edited Transcript of ASND earnings conference call or presentation 28-Mar-18 8:30pm GMTEdited Transcript of ASND earnings conference call or presentation 28-Mar-18 8:30pm GMT
finance.yahoo.com - March 29 at 9:53 AM
Ascendis Pharma A/S Reports Full Year 2017 Financial ResultsAscendis Pharma A/S Reports Full Year 2017 Financial Results
finance.yahoo.com - March 28 at 4:24 PM
Ascendis Pharma A/S to Host Earnings CallAscendis Pharma A/S to Host Earnings Call
finance.yahoo.com - March 28 at 4:24 PM
BidaskClub Upgrades Ascendis Pharma A/S (ASND) to BuyBidaskClub Upgrades Ascendis Pharma A/S (ASND) to Buy
www.americanbankingnews.com - March 27 at 4:00 PM
JPMorgan Chase & Co. Raises Ascendis Pharma A/S (ASND) Price Target to $75.00JPMorgan Chase & Co. Raises Ascendis Pharma A/S (ASND) Price Target to $75.00
www.americanbankingnews.com - March 21 at 6:06 PM
Ascendis Pharma (ASND) PT Raised to $75 at JPMorgan; Pipeline Updates Increase Our ConfidenceAscendis Pharma (ASND) PT Raised to $75 at JPMorgan; 'Pipeline Updates Increase Our Confidence'
www.streetinsider.com - March 21 at 10:39 AM
Ascendis Pharma A/S (ASND) Set to Announce Earnings on WednesdayAscendis Pharma A/S (ASND) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - March 21 at 2:14 AM
Ascendis Pharma A/Ss (ASND) Hold Rating Reaffirmed at Credit Suisse GroupAscendis Pharma A/S's (ASND) Hold Rating Reaffirmed at Credit Suisse Group
www.americanbankingnews.com - March 20 at 11:58 AM
Ascendis Pharma Announces Two Posters on Rare Disease Pipeline Programs at ENDO 2018Ascendis Pharma Announces Two Posters on Rare Disease Pipeline Programs at ENDO 2018
finance.yahoo.com - March 19 at 9:41 AM
$580,000.00 in Sales Expected for Ascendis Pharma A/S (ASND) This Quarter$580,000.00 in Sales Expected for Ascendis Pharma A/S (ASND) This Quarter
www.americanbankingnews.com - March 19 at 4:16 AM
-$0.92 Earnings Per Share Expected for Ascendis Pharma A/S (ASND) This Quarter-$0.92 Earnings Per Share Expected for Ascendis Pharma A/S (ASND) This Quarter
www.americanbankingnews.com - March 17 at 1:30 PM
Ascendis Pharma A/S (ASND) Given Consensus Rating of "Buy" by AnalystsAscendis Pharma A/S (ASND) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - March 7 at 5:51 PM
73,771 Shares in Ascendis Pharma A/S (ASND) Purchased by University of Notre Dame DU Lac73,771 Shares in Ascendis Pharma A/S (ASND) Purchased by University of Notre Dame DU Lac
www.americanbankingnews.com - March 6 at 3:40 PM
Ascendis Pharma A/S (ASND) Holdings Trimmed by VHCP Management II LLCAscendis Pharma A/S (ASND) Holdings Trimmed by VHCP Management II LLC
www.americanbankingnews.com - March 6 at 10:50 AM
Emory University Trims Holdings in Ascendis Pharma A/S (ASND)Emory University Trims Holdings in Ascendis Pharma A/S (ASND)
www.americanbankingnews.com - March 4 at 2:59 PM
Ascendis Pharma A/S (ASND) Stock Rating Upgraded by Zacks Investment ResearchAscendis Pharma A/S (ASND) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - March 1 at 6:36 PM
Wedbush Research Analysts Decrease Earnings Estimates for Ascendis Pharma A/S (ASND)Wedbush Research Analysts Decrease Earnings Estimates for Ascendis Pharma A/S (ASND)
www.americanbankingnews.com - March 1 at 7:20 AM
Ascend Capital LLC Purchases New Stake in Ascendis Pharma A/S (ASND)Ascend Capital LLC Purchases New Stake in Ascendis Pharma A/S (ASND)
www.americanbankingnews.com - March 1 at 4:42 AM
Research Analysts Issue Forecasts for Ascendis Pharma A/Ss FY2022 Earnings (ASND)Research Analysts Issue Forecasts for Ascendis Pharma A/S's FY2022 Earnings (ASND)
www.americanbankingnews.com - February 28 at 4:50 PM
Ascendis Pharma A/S (ASND) Expected to Announce Earnings of -$0.89 Per ShareAscendis Pharma A/S (ASND) Expected to Announce Earnings of -$0.89 Per Share
www.americanbankingnews.com - February 28 at 1:40 PM
Ascendis Pharma A/S (ASND) Rating Reiterated by WedbushAscendis Pharma A/S (ASND) Rating Reiterated by Wedbush
www.americanbankingnews.com - February 26 at 4:20 PM

SEC Filings

Ascendis Pharma (NASDAQ:ASND) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Ascendis Pharma (NASDAQ:ASND) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Ascendis Pharma (NASDAQ ASND) Stock Chart for Tuesday, May, 22, 2018

Loading chart…

This page was last updated on 5/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.